Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
FATE
FATE
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
FATE News
Avant Technologies Leads Transformation in Healthcare Market
Jan 26 2026
PRnewswire
Avant Technologies Leads Medical Innovation with Next-Gen Treatments
Jan 26 2026
Newsfilter
Avant Technologies Unveils Cell Encapsulation Tech to Address 589 Million Diabetes Patients' Needs
Jan 23 2026
Globenewswire
Avant Technologies Unveils Cell Encapsulation Tech, Tapping into Diabetes Market Potential
Jan 23 2026
Newsfilter
Needham Maintains Hold Rating on Fate Therapeutics
Oct 27 2025
Benzinga
Fate Therapeutics Unveils New Clinical Findings at ACR Convergence 2025 Highlighting Immune Remodeling and Lasting Responses in Systemic Lupus Erythematosus Patients Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
Oct 26 2025
Newsfilter
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
Aug 14 2025
Newsfilter
Fate Therapeutics Appoints Matthew Abernethy to Board of Directors, Timothy P. Coughlin Steps Down
May 30 2025
NASDAQ.COM
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
May 30 2025
Newsfilter
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
May 28 2025
Newsfilter
Needham Reiterates Hold on Fate Therapeuticsto Hold
May 14 2025
Benzinga
Fate Therapeutics GAAP EPS of -$0.32 beats by $0.07, revenue of $1.63M beats by $0.45M
May 13 2025
SeekingAlpha
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
Apr 29 2025
Newsfilter
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
Apr 14 2025
Newsfilter
Fate Therapeutics gets RMAT status from FDA for Lupus treatment
Apr 14 2025
SeekingAlpha
Analysts Have Conflicting Sentiments on These Healthcare Companies: Fate Therapeutics (FATE) and Stevanato Group (STVN)
Mar 06 2025
Business Insider
Show More News
